MyGene completed Series C funding and gained NMPA approval for lung cancer PCR multi-gene CDx

Guangzhou MyGene Medical Technology Co., Ltd. announced the completion of several hundred million yuan in Series C financing. This round of financing was led by Efung Capital, the funds will be used for R&D and product registrationfor the IVD products.

At the same time, the company’s self-developed PCR multi-gene companion diagnostic kit for lung cancer was also approved for marketing by the National Medical Products Administration (NMPA) (Registration No. 20223401432), becoming the first PCR multi-gene companion diagnostic kit for non-small cell lung cancer in the Chinese market.

The MyGene lung cancer PCR multi-gene companion diagnostic kit covers the core genes required by the national guidelines for the diagnosis and treatment of lung cancer. It can detect the core driver genes in multiple non-small cell lung cancers such as EGFR, ALK, and ROS1. Its companion diagnostic function of targeted drugs has been fully verified with clinical validity. The product also has the advantages of simple operation and fast results, which can effectively solve the clinical treatment and diagnostic needs of patients with advanced NSCLC.

About MyGene

Founded in 2015, Guangzhou MyGene Medical Technology Co., Ltd. is headquartered in Guangzhou, and has a cutting-edge R&D center in Silicon Valley, San Francisco, USA. MyGene specializes in the R&D, manufacture, distribution and sales of molecular diagnostic products, and is committed to promoting the application of next-generation high-throughput sequencing technology in the field of precision medicine.

Using PCR and NGS technology platforms simultaneously, MyGene has developed a series of molecular diagnostic products for tumor diagnosis, typing, monitoring and screening, covering the whole process of cancer diagnosis and treatment. Since its establishment, MyGene has always insisted on developing molecular diagnostic products suitable for patients, doctors and medical institutions.